Thyrotropin-releasing hormone in schizophrenia
Abstract
Oral administration of thyrotropin-releasing hormone (TRH) caused deterioration in the clinical status of seven out of nine schizophrenic men. This change was particularly apparent in the four patients diagnosed as paranoid schizophrenics. Such changes might be expected from a drug with properties similar to amphetamine.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
